Zobrazeno 1 - 10
of 430
pro vyhledávání: '"T. Olin"'
Autor:
Abdul Salam Khan, T. Olin, Lotta Hansson, Mohammad Hojjat-Farsangi, C. Norström, J. Schultz, Amir Hossein Daneshmanesh, M. Norin, L.-S. Rathje, Pedram Kharaziha, Anders Österborg, Jayant Shetye, C. Löfberg, E. Olsson, Ali Moshfegh, J. Vågberg, Parviz Kokhaei, S. Byström, Fariba Mozaffari, Håkan Mellstedt
Publikováno v:
Leukemia
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Shaff, T. B. H. Kuiper, T. Olin, Shinji Horiuchi, L. P. Teitelbaum, Danny C. Price, L. White, Graham Baines, I. Zaw, Sander Weinreb, Lincoln J. Greenhill, Manuel Franco, Stephen D Smith
Publikováno v:
Journal of Astronomical Instrumentation.
A dual beam, dual polarization, low noise receiver has been installed at a Cassegrain focus of the NASA 70[Formula: see text]m antenna near Canberra, Australia. It operates in five pairs of 1[Formula: see text]GHz bands from 17 to 27[Formula: see tex
Autor:
T Olin, John Pernow, R Fritsche Danielson, Ioakim Spyridopoulos, S Abdelmoaty, M Wagberg, Anders Gabrielsen, Helen M. Arthur
Publikováno v:
European Heart Journal. 40
Background Fractalkine is a chemokine that mediates recruitment and extravasation of CX3CR1-expressing subsets of leukocytes and monocytes and has been implicated in the inflammation-driven pathology of cardiovascular disease. More specifically, frac
Publikováno v:
Journal of the American Podiatric Medical Association. 104:479-485
BackgroundEfinaconazole 10% solution is a new triazole antifungal agent developed for the topical treatment of onychomycosis. This article reviews the pooled results of the two pivotal clinical trials of this drug that have been performed in the Unit
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wayne J. Morgan, Michael D. Cabana, Cori L. Daines, W. A. Gower, Wanda Phipatanakul, Rachel G. Robison, Stephen C. Lazarus, Harsha Vardhan Hampasandra Madan Kumar, Jyothi Marbin, Fernando D. Martinez, Hengameh H. Raissy, James N. Moy, Jonathan M. Gaffin, Michael E. Wechsler, Elliot Israel, Kristie R. Ross, Shannon Thyne, Ngoc P. Ly, Ross Myers, Susan J. Boehmer, R. F. Lemanske, Stephen P. Peters, Ian M. Paul, Kathryn V. Blake, Deborah A. Gentile, Michael O. Daines, Sachin N. Baxi, Fernando Holguin, John J. Lima, Avraham Beigelman, William J. Sheehan, C. A. Sorkness, J. T. Olin, Stanley J. Szefler, M. Benson, Leonard B. Bacharier, D. J. Jackson, Ronina A. Covar, Jason E. Lang, Anne M. Fitzpatrick, James F. Chmiel, Jacqueline A. Pongracic, David T. Mauger
Publikováno v:
The New England journal of medicine, vol 375, iss 7
BackgroundStudies have suggested an association between frequent acetaminophen use and asthma-related complications among children, leading some physicians to recommend that acetaminophen be avoided in children with asthma; however, appropriately des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aa9a79799ee7b40f329ac7c6203ca21
https://escholarship.org/uc/item/31v6d83t
https://escholarship.org/uc/item/31v6d83t
Publikováno v:
International Journal of Clinical Practice. 65:465-471
Summary Aim: The cholinesterase inhibitor rivastigmine is available in both oral and transdermal forms. The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivast
Publikováno v:
American Journal of Alzheimer's Disease & Other Dementiasr. 26:65-71
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD). Methods: Post hoc analysis of a 24-week, prospective, int
Publikováno v:
International Journal of Geriatric Psychiatry. 26:1236-1243
Objectives The cholinesterase inhibitor rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease (AD). This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of deme